$TGTX
TG THERAPEUTICS, INC.

2023 Q1 Form 10-K Financial Statement

#000155837023002610 Filed on March 01, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $7.803M $80.00K $2.785M
YoY Change 287.05% -96.55% -58.36%
Cost Of Revenue $857.0K $3.000K $265.0K
YoY Change 261.6% -98.57% -66.46%
Gross Profit $6.946M $77.00K $2.520M
YoY Change 290.44% -96.35% -57.28%
Gross Profit Margin 89.02% 96.25% 90.48%
Selling, General & Admin $28.07M $22.50M $70.01M
YoY Change 36.19% -30.57% -45.35%
% of Gross Profit 404.09% 29225.97% 2778.06%
Research & Development $15.87M $29.64M $125.4M
YoY Change -66.97% -52.69% -43.68%
% of Gross Profit 228.48% 38487.01% 4974.29%
Depreciation & Amortization $68.00K $73.00K $303.0K
YoY Change -10.53% -8.75% 7.45%
% of Gross Profit 0.98% 94.81% 12.02%
Operating Expenses $44.80M $52.14M $195.6M
YoY Change -34.97% -45.15% -44.34%
Operating Profit -$36.99M -$52.06M -$192.8M
YoY Change -44.68% -43.99% -44.07%
Interest Expense $2.844M -$2.862M $10.19M
YoY Change 6.76% 165.25% 80.76%
% of Operating Profit
Other Income/Expense, Net -$2.240M $1.930M -$5.496M
YoY Change 4.62% 180.52% 65.0%
Pretax Income -$39.23M -$52.99M -$198.3M
YoY Change -43.15% -43.22% -43.02%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$39.23M -$52.99M -$198.3M
YoY Change -43.15% -43.22% -43.02%
Net Earnings / Revenue -502.78% -66242.5% -7121.54%
Basic Earnings Per Share -$0.28 -$1.46
Diluted Earnings Per Share -$0.28 -$0.39 -$1.46
COMMON SHARES
Basic Shares Outstanding 146.4M 145.3M 135.4M
Diluted Shares Outstanding 140.3M 135.4M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $139.7M $161.7M $161.7M
YoY Change -40.09% -48.64% -48.64%
Cash & Equivalents $61.47M $102.3M $102.3M
Short-Term Investments $78.24M $59.37M $59.37M
Other Short-Term Assets $4.458M $2.359M $6.596M
YoY Change 10.9% -18.2% -55.47%
Inventory $27.22M $0.00
Prepaid Expenses
Receivables $8.623M $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $184.8M $168.3M $168.3M
YoY Change -23.71% -49.16% -49.16%
LONG-TERM ASSETS
Property, Plant & Equipment $237.0K $307.0K $10.82M
YoY Change -54.94% -48.83% -2.22%
Goodwill $799.0K $799.0K
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00 $12.40M $12.40M
YoY Change -100.0% -65.09% -65.09%
Other Assets $1.276M $1.273M $1.273M
YoY Change 0.87% 0.71% 0.71%
Total Long-Term Assets $12.58M $25.30M $25.30M
YoY Change -79.32% -48.01% -48.01%
TOTAL ASSETS
Total Short-Term Assets $184.8M $168.3M $168.3M
Total Long-Term Assets $12.58M $25.30M $25.30M
Total Assets $197.4M $193.6M $193.6M
YoY Change -34.87% -49.01% -49.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $57.09M $42.02M $42.02M
YoY Change 14.95% -18.08% -18.08%
Accrued Expenses $4.763M $10.01M $10.01M
YoY Change 52.91% -13.7% -13.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $63.08M $53.20M $53.20M
YoY Change 15.41% -18.63% -18.63%
LONG-TERM LIABILITIES
Long-Term Debt $96.50M $71.14M $71.14M
YoY Change 43.5% 6.51% 6.51%
Other Long-Term Liabilities $10.35M $10.65M $10.65M
YoY Change -3.64% 3.35% 3.35%
Total Long-Term Liabilities $96.50M $71.14M $81.78M
YoY Change 43.5% 6.51% 6.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.08M $53.20M $53.20M
Total Long-Term Liabilities $96.50M $71.14M $81.78M
Total Liabilities $169.9M $135.0M $135.0M
YoY Change 28.11% -5.26% -5.26%
SHAREHOLDERS EQUITY
Retained Earnings -$1.600B -$1.527B
YoY Change 14.29% 14.93%
Common Stock $149.0K $146.0K
YoY Change 2.76% 2.1%
Preferred Stock
YoY Change
Treasury Stock (at cost) $200.0K
YoY Change -14.53%
Treasury Stock Shares $41.31K
Shareholders Equity $27.43M $58.59M $58.59M
YoY Change
Total Liabilities & Shareholders Equity $197.4M $193.6M $193.6M
YoY Change -34.87% -49.01% -49.01%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$39.23M -$52.99M -$198.3M
YoY Change -43.15% -43.22% -43.02%
Depreciation, Depletion And Amortization $68.00K $73.00K $303.0K
YoY Change -10.53% -8.75% 7.45%
Cash From Operating Activities -$59.90M -$23.87M -$176.2M
YoY Change -12.79% -72.53% -40.41%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $3.000K $14.00K
YoY Change -100.0% -103.75% -96.51%
Acquisitions
YoY Change
Other Investing Activities -$6.168M $16.27M -$20.00M
YoY Change -85.87% 383.14% -29084.06%
Cash From Investing Activities -$6.168M $16.27M -$20.01M
YoY Change -85.88% 394.8% 5928.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.24M 49.00K -391.0K
YoY Change -3069.18% -99.91% -100.94%
NET CHANGE
Cash From Operating Activities -59.90M -23.87M -176.2M
Cash From Investing Activities -6.168M 16.27M -20.01M
Cash From Financing Activities 25.24M 49.00K -391.0K
Net Change In Cash -40.83M -7.552M -196.6M
YoY Change -63.93% -72.66% -22.77%
FREE CASH FLOW
Cash From Operating Activities -$59.90M -$23.87M -$176.2M
Capital Expenditures $0.00 $3.000K $14.00K
Free Cash Flow -$59.90M -$23.87M -$176.2M
YoY Change -12.8% -72.51% -40.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.46
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.63
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.42
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
135411258
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
132222753
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115333693
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001001316
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1527033000
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2014Q3 tgtx Number Of Days Rights Become Exercisable
NumberOfDaysRightsBecomeExercisable
P10D
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
600000
CY2022Q4 us-gaap Goodwill
Goodwill
799000
CY2021Q4 us-gaap Goodwill
Goodwill
799000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
938000
CY2021 tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
1023000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2100000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2080000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1913000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6541000
CY2022 tgtx Effective Income Tax Rate Reconciliation Nondeductible Expense Officer Compensation Limitation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationLimitation
4391000
CY2021 tgtx Effective Income Tax Rate Reconciliation Nondeductible Expense Officer Compensation Limitation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficerCompensationLimitation
439000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
374000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
428000
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1065
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
1-32639
CY2022 dei Entity Registrant Name
EntityRegistrantName
TG THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
3020 Carrington Mill Blvd, Suite 475
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Morrisville
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27560
CY2022 dei City Area Code
CityAreaCode
212
CY2022 dei Local Phone Number
LocalPhoneNumber
554-4484
CY2022 dei Security12b Title
Security12bTitle
Common Stock
CY2022 dei Trading Symbol
TradingSymbol
TGTX
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2022 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
false
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
564449606
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
146363127
CY2022 dei Auditor Name
AuditorName
KPMG LLP
CY2022 dei Auditor Location
AuditorLocation
New York, NY
CY2022 dei Auditor Firm
AuditorFirmId
185
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102304000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298887000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
59374000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
15876000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1389000
CY2022Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
4237000
CY2021Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
11929000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2359000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2884000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
168274000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
330965000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1273000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1264000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
12404000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
35533000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8888000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8629000
CY2022Q4 tgtx Leasehold Interest
LeaseholdInterest
1627000
CY2021Q4 tgtx Leasehold Interest
LeaseholdInterest
1839000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
307000
CY2022Q4 us-gaap Assets
Assets
193572000
CY2021Q4 us-gaap Assets
Assets
379629000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
42019000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
51294000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1169000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1512000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
975000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1581000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1437000
CY2022Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
8432000
CY2021Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
10166000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53201000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65384000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
305000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
457000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
71135000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
66788000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10344000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9847000
CY2022Q4 us-gaap Liabilities
Liabilities
134985000
CY2021Q4 us-gaap Liabilities
Liabilities
142476000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
146426697
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
143292043
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
146385388
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
143250734
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
146000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
143000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1585708000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1565942000
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
234000
CY2021Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
234000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1527033000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1328698000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
58587000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
237153000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
193572000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
379629000
CY2022 us-gaap Revenues
Revenues
2785000
CY2021 us-gaap Revenues
Revenues
6689000
CY2020 us-gaap Revenues
Revenues
152000
CY2022 tgtx Cost Of Product Revenue
CostOfProductRevenue
265000
CY2021 tgtx Cost Of Product Revenue
CostOfProductRevenue
790000
CY2022 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
13224000
CY2021 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
24047000
CY2020 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
13962000
CY2022 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
112128000
CY2021 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
198532000
CY2020 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
151934000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125352000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
222579000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
165896000
CY2022 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
5961000
CY2021 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
37227000
CY2020 tgtx Non Cash Compensation Selling General And Administrative Expenses
NonCashCompensationSellingGeneralAndAdministrativeExpenses
66327000
CY2022 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
64046000
CY2021 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
90863000
CY2020 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
41523000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
70007000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
128090000
CY2020 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
107850000
CY2022 us-gaap Operating Expenses
OperatingExpenses
195624000
CY2021 us-gaap Operating Expenses
OperatingExpenses
351459000
CY2020 us-gaap Operating Expenses
OperatingExpenses
273746000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-192839000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-344770000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-273594000
CY2022 us-gaap Interest Expense
InterestExpense
10191000
CY2021 us-gaap Interest Expense
InterestExpense
5638000
CY2020 us-gaap Interest Expense
InterestExpense
6329000
CY2022 us-gaap Other Income
OtherIncome
4695000
CY2021 us-gaap Other Income
OtherIncome
2307000
CY2020 us-gaap Other Income
OtherIncome
542000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5496000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3331000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5787000
CY2022 us-gaap Profit Loss
ProfitLoss
-198335000
CY2021 us-gaap Profit Loss
ProfitLoss
-348101000
CY2020 us-gaap Profit Loss
ProfitLoss
-279381000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.46
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.63
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.42
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135411258
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132222753
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115333693
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38615000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
146000
CY2020 tgtx Offering Costs
OfferingCosts
29900000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
462229000
CY2020Q4 tgtx Offering Costs At Market
OfferingCostsAtMarket
4000000.0
CY2020 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
217452000
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
80289000
CY2020 us-gaap Profit Loss
ProfitLoss
-279381000
CY2020Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
519350000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
216000
CY2021 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2195000
CY2021 tgtx Offering Costs
OfferingCosts
-204000
CY2021Q4 tgtx Offering Costs At Market
OfferingCostsAtMarket
100000
CY2021 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
2423000
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
61274000
CY2021 us-gaap Profit Loss
ProfitLoss
-348101000
CY2021Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
237153000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
584000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
19185000
CY2022 us-gaap Profit Loss
ProfitLoss
-198335000
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
41309
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
58587000
CY2022 us-gaap Profit Loss
ProfitLoss
-198335000
CY2021 us-gaap Profit Loss
ProfitLoss
-348101000
CY2020 us-gaap Profit Loss
ProfitLoss
-279381000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
19185000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
61274000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
80289000
CY2022 us-gaap Depreciation
Depreciation
303000
CY2021 us-gaap Depreciation
Depreciation
282000
CY2020 us-gaap Depreciation
Depreciation
158000
CY2022 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
331000
CY2021 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
517000
CY2020 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
30000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1844000
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1080000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
925000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
212000
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
212000
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
216000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2715000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1896000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2325000
CY2022 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
116000
CY2021 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
578000
CY2020 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-748000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-8181000
CY2021 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
8508000
CY2020 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-2257000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1389000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1389000
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-11010000
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
15991000
CY2020 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
11631000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2332000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2012000
CY2020 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1988000
CY2022 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
2277000
CY2021 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-16146000
CY2020 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-31505000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2020 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-176170000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-295634000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-214507000
CY2022 tgtx Proceeds From Maturities
ProceedsFromMaturities
87275000
CY2021 tgtx Proceeds From Maturities
ProceedsFromMaturities
55600000
CY2020 tgtx Proceeds From Maturities
ProceedsFromMaturities
43250000
CY2022 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
107274000
CY2021 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
55531000
CY2020 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
67403000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
401000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
357000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20013000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-332000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-24510000
CY2022 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-975000
CY2021 us-gaap Proceeds From Repayments Of Secured Debt
ProceedsFromRepaymentsOfSecuredDebt
-30000000
CY2021 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
2219000
CY2020 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
679680000
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
584000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
216000
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
147000
CY2021 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
70000000
CY2021 tgtx Repayment Of Offering Costs
RepaymentOfOfferingCosts
1016000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-391000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41419000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
679827000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-196574000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-254547000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
440810000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300151000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554698000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113888000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103577000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300151000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554698000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102304000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
298887000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
553439000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
1273000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1264000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1259000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103577000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
300151000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
554698000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
5445000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
3466000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
4501000
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
174100000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">USE OF ESTIMATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue, accrued clinical trial expenses and stock-based compensation. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p>
CY2022Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
CY2021Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
CY2022Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">CREDIT RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents and short-term investments with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>
CY2022 us-gaap Revenue Recognition Sales Returns Reserve For Sales Returns
RevenueRecognitionSalesReturnsReserveForSalesReturns
600000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1601000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
360000
CY2022 tgtx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityInterestAccruedIncludedInEarnings
1073000
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1190000
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
243000
CY2022Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
4200000
CY2021Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
11900000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12650658
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13280608
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11976276
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12650658
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13280608
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11976276
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022 tgtx Revenue Gross
RevenueGross
4119000
CY2021 tgtx Revenue Gross
RevenueGross
8172000
CY2022 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
367000
CY2021 us-gaap Administrative Fees Expense
AdministrativeFeesExpense
840000
CY2022 tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
182000
CY2021 tgtx Trade Discounts And Allowances
TradeDiscountsAndAllowances
383000
CY2022 tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
229000
CY2021 tgtx Government Rebates And Co Payment Assistance
GovernmentRebatesAndCoPaymentAssistance
372000
CY2022 tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
708000
CY2021 tgtx Sales Returns And Allowances
SalesReturnsAndAllowances
40000
CY2022 tgtx Gross To Net Adjustments
GrossToNetAdjustments
1486000
CY2021 tgtx Gross To Net Adjustments
GrossToNetAdjustments
1635000
CY2022 tgtx Net Product Revenue
NetProductRevenue
2633000
CY2021 tgtx Net Product Revenue
NetProductRevenue
6537000
CY2022Q4 tgtx Gross Net Accruals
GrossNetAccruals
200000
CY2021Q4 tgtx Gross Net Accruals
GrossNetAccruals
400000
CY2022Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
71778000
CY2022Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
1482000
CY2022Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
70296000
CY2021Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
51409000
CY2021Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
164000
CY2021Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
51245000
CY2022Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
243000
CY2022Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
243000
CY2021Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
360000
CY2021Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
360000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.001
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
100.00
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
175000000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
200000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2605730
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.73
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M1D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11706110
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
75000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.21
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
35814
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.10
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
118750
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.16
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2526166
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.99
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
115472832
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
52694
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.10
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
5935
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.10
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2467537
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.06
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M26D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
29503551
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2975000
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.00
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
142409
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.10
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
164443
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.84
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5135685
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.10
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y1M2D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
25064799
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2107583
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.70
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M20D
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11238429
CY2022Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
70000000
CY2021Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
70000000
CY2022Q4 tgtx End Of Term Fee
EndOfTermFee
6667000
CY2021Q4 tgtx End Of Term Fee
EndOfTermFee
5140000
CY2022Q4 tgtx Long Term Debt Gross
LongTermDebtGross
76667000
CY2021Q4 tgtx Long Term Debt Gross
LongTermDebtGross
75140000
CY2022Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
5532000
CY2021Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
7377000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
71135000
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
67763000
CY2022Q4 tgtx Long Term Debt Excluding Principal Payments
LongTermDebtExcludingPrincipalPayments
71135000
CY2021Q4 tgtx Long Term Debt Excluding Principal Payments
LongTermDebtExcludingPrincipalPayments
67763000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
975000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
71135000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
66788000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
2671000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
2154000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
2656000
CY2022 us-gaap Lease Cost
LeaseCost
2671000
CY2021 us-gaap Lease Cost
LeaseCost
2154000
CY2020 us-gaap Lease Cost
LeaseCost
2656000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1581000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1437000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10344000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9847000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11925000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11284000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2375000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2388000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
17397000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5472000
CY2022Q4 tgtx Operating Lease Liability Incremental Borrowing Rate
OperatingLeaseLiabilityIncrementalBorrowingRate
11925000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
400400000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
367400000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
303729000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
295985000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
42031000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
35665000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
10325000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
32356000
CY2022Q4 tgtx Deferred Tax Asset Disallowed Interest
DeferredTaxAssetDisallowedInterest
3882000
CY2021Q4 tgtx Deferred Tax Asset Disallowed Interest
DeferredTaxAssetDisallowedInterest
2434000
CY2022Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
39411000
CY2021Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
0
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
985000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1006000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
400363000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
367446000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
400363000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
367446000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-198335000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-348101000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-279381
CY2022 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-41650000
CY2021 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-73101000
CY2020 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-58670
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-7242000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3445000
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-10801
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
6389000
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
8337000
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
5265
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
17599000
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-6726000
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-1558
CY2022 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
0
CY2021 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
0
CY2020 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
-14763
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
32917000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
90742000
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
89992
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
91600000
CY2022Q4 us-gaap Contractual Obligation
ContractualObligation
91562000
CY2022Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
2375000
CY2022Q4 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
78653000
CY2022Q4 us-gaap Contractual Obligation Due In Fourth And Fifth Year
ContractualObligationDueInFourthAndFifthYear
3993000
CY2022Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
6541000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
2200000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
2700000

Files In Submission

Name View Source Status
0001558370-23-002610-index-headers.html Edgar Link pending
0001558370-23-002610-index.html Edgar Link pending
0001558370-23-002610.txt Edgar Link pending
0001558370-23-002610-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tgtx-20221231.xsd Edgar Link pending
tgtx-20221231x10k.htm Edgar Link pending
tgtx-20221231x10k001.jpg Edgar Link pending
tgtx-20221231xex21d1.htm Edgar Link pending
tgtx-20221231xex23d1.htm Edgar Link pending
tgtx-20221231xex23d2.htm Edgar Link pending
tgtx-20221231xex31d1.htm Edgar Link pending
tgtx-20221231xex31d2.htm Edgar Link pending
tgtx-20221231xex32d1.htm Edgar Link pending
tgtx-20221231xex32d2.htm Edgar Link pending
tgtx-20221231_cal.xml Edgar Link unprocessable
tgtx-20221231_def.xml Edgar Link unprocessable
tgtx-20221231_lab.xml Edgar Link unprocessable
tgtx-20221231_pre.xml Edgar Link unprocessable
tgtx-20221231x10k_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable